SP1-mediated long noncoding RNA POU3F3 accelerates the cervical cancer through miR-127-5p/FOXD1 - 31/07/19

pages | 7 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Graphical Abstract |
Highlights |
• | LncRNA POU3 F3 is up-regulated in the cervical cancer tissue specimens and cells. |
• | POU3 F3 promotes the proliferation, invasion and tumor growth of cervical cancer cells. |
• | The transcriptional expression of POU3 F3 is activated by the transcription factor SP1. |
• | LncRNA POU3 F3 acts as an oncogene in the cervical cancer tumorigenesis via regulating miR-127-5p/FOXD1 axis. |
Abstract |
Emerging evidence supports the critical roles of long noncoding RNA (lncRNA) in cervical cancer. However, the pathological roles of lncRNA POU3 F3 in the cervical cancer tumorigenesis are still elusive. POU3 F3 was validated to be up-regulated in the cervical cancer tissue specimens and cells comparing with normal controls. Moreover, the ectopic overexpression of POU3 F3 was closely correlated with poor prognosis. In vitro, POU3 F3 promoted the proliferation, invasion of cervical cancer cells. In vivo, POU3 F3 knockdown repressed the tumor growth of cervical cancer cells. The transcriptional expression of POU3 F3 was activated by the transcription factor SP1. Mechanically, POU3 F3 acted as the sponge to target miR-127-5p, while miR-127-5p bind with the 3′-UTR of FOXD1 gene. In conclusion, our data verifies that lncRNA POU3 F3, induced by transcription factor SP1, acts as an oncogene in the cervical cancer tumorigenesis via regulating miR-127-5p/FOXD1 axis, providing a possible therapeutic target for cervical cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Cervical cancer, POU3F3, SP1, miR-127-5p, FOXD1
Plan
Vol 117
Article 109133- septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?